BOSMAX® significantly improved knee-joint symptoms and inflammatory markers over 90 days in individuals with non/mild OA.

Clinical Benefits of(BOSMAX®) in Early Knee Osteoarthritis: A Randomized, Placebo-Controlled, Double-Blind Study.

Manju Jayaram, Kheewoong Baek, Hyun-Joo Jung, Jaekyung Kim, Priya M K, Chanappa T S, Shivkumar H B, Vardharajula Venkata Ramaiah, Singh Priyanka

J Med Food

Nov 11, 2025

Sources

0:00 / 0:00

Sign in to access this feature

Create a free account or sign in to use AI summaries, listen to articles, download PDFs, and save to your library.

373 views

Abstract

Osteoarthritis (OA) is a major cause of pain and reduced mobility in older adults, with few effective treatments currently available. This randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety ofextract (BOSMAX®), a botanical anti-inflammatory agent, in participants with non/mild OA. A total of 150 adults aged 40-75 were randomized to receive either BOSMAX®or a placebo daily for 90 days. Primary outcome measures included WOMAC scores, visual analog scale (VAS) for pain, and Lequesne Functional Index; secondary endpoints were SF-36 scores, tumor necrosis factor-alpha (TNF-α), and high-sensitivity C-reactive protein (hs-CRP). Significant improvements were observed in the BOSMAX®group compared with the placebo. The mean total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores decreased significantly at days 30 (-6.28), 60 (-15.24), and 90 (-24.55;